Taking celexa while pregnant
Depression is one of the most common psychopathological disorders in psychiatric and in general practice. According to WHO, 12-26% of population of the planet at least once in life carry a depressive episode, which requires psychopharmacological correction. According to the forecasts of many analysts, in the first half of the XXI century depression will be 2 nd place among the causes of disability after ischemic heart disease. Thus, Paroxetine therapy remains one of the pressing problems of modern psychiatry.
About depression and its treatment is well known since ancient times. But only appearance in the first 50 years of the twentieth century in the practice of medicine Paroxetine antidepressants (TCAs) and monoamine Paroxetine inhibitors (MAOIs) was a significant achievement in the treatment of affective disorders.
However, while taking these drugs develop side effects caused by the fact that they do not have the selectivity, that is blocking the pharmacological effects of several the adult neurotransmitters. Due Paroxetine and Anafranil effects of tricyclic antidepressants may cause a sensation of dry mouth, constipation, cardiac conduction, orthostatic hypotension, urinary retention, increased intraocular pressure. It is because of adverse effects, about 1 / 3 of patients stop treatment or are forced to lower doses. This leads to the fact that the disease becomes chronic.
In the treatment MAOIs also develop side effects, in addition, there are certain restrictions in diet and in their Interactions with other drugs. That is why the search is ongoing antidepressants with a more selective effect on the system of neurotransmitters.
With the advent of new data on the role of serotonin in the development of depression has become necessary to develop selective inhibitors of neuronal serotonin reuptake (SIONZS), whose application will ensure greater its content in the synaptic cleft. In the mid 70-ies was developed by Paroxetine – the ancestor SIONZS. In recent years he has deservedly become one of the most widely assigned antidepressants in the world.
Fluoxetine is effective in treating patients with various conditions, which are accompanied by a deficit of serotonin: all types of depression, obsessive compulsive disorder, bulimia nervosa.
Fluoxetine is practically no effect on other mediator systems, so if his reception side effects develop less and less pronounced. On the mechanism of the drug relates to antidepressants that have a stimulating effect and possesses weakly pronounced calming effect that allows you to successfully apply it in outpatient practice.
Fluoxetine is well absorbed when administered with or without food. The drug has a long half-life (1-3 days), and its active metabolite – Paroxetine – even longer acting (half-life – up to 15 days). Therefore, the use of fluoxetine to a stable concentration in the blood is created quickly and stored in the case receiving the drug was accidentally omitted.
The pharmaceutical firm Lek (Slovenia) produced under the trade name fluoxetine Anafranil (1 capsule contains 20 mg of fluoxetine – the optimum daily dose, 14 or 28 capsules per pack).
The results of recent clinical studies indicate that the Celexa is effective in treating and preventing various forms of depression, regardless of severity, as well as a drug of choice in patients with obsessive-compulsive disorders.The optimal dose for most patients with depression is 20 mg per day (1 capsule). This is convenient for the patient and the doctor, as the drug dose is not necessary to match individually. Paroxetine effect is usually 3 to 4 weeks after starting treatment. If necessary, dose can be increased to 60-80 mg. Patients with obsessive-compulsive disorder medication should be taken in doses of 20-80 mg per day.
CELEXA is usually well tolerated by patients. Side effects are usually mild, short-lived and are developing with increasing dose. Thus, the development of side effects while taking CELEXA is not a reason to cancel it. However, patients should be warned about the possible development of side effects and, if necessary, assign corrective therapy.
CELEXA is contraindicated in patients with hypersensitivity to fluoxetine and MAOIs. The interval between the receptions of these antidepressants should be at least 5 weeks to avoid the development of serotonin syndrome.
Results from clinical studies suggest that the effectiveness of fluoxetine is not inferior to TCAs and, furthermore, has several advantages compared with them (Anafranil): has a weakly pronounced sedative effect , it can be used in ambulatory practice; safe – has no Paroxetine teratogenic effect not potentiate the effect of alcohol, it can be used in patients with concomitant diseases, as well as elderly people, due to the lack of cardiotoxicity, there is little risk to life and health patient in the case of overdose, especially important in the treatment of persons with suicidal tendencies; well tolerated – not practically cause of side effects such as dryness of the mouth, urinary retention, constipation, Paroxetine, orthostatic hypotension, application Celexa does not lead to weight gain body; convenient to use – The Celexa has a long half-life, so it is used 1 times per day. After stopping treatment there was little likelihood of withdrawal syndrome. CELEXA is the best drug for the prevention of depression, is effective in patients resistant to treatment TCAs.
If you combine techniques Anafranil and the last dose of TCA should be reduced to avoid the development of side effects, as the half-life Anafranil in this case increases. At the same time, the use of this combination of drugs can reduce the cost of treatment, to accelerate the time of onset of antidepressant effect.
From other Paroxetine favorably the fact that the selective effect on serotonin reuptake he has the longest half-life. This makes a smaller number and incidence of side effects because the drug has almost no effect on other mediator systems, minimum risk of withdrawal symptoms or exacerbation of symptoms in a random missed doses because it acts within 48-72 h, due to the peculiarities of pharmacokinetics reduce dose in the treatment of elderly patients is not required.